CHMP scolds AB Sci­ence (again) for ma­sitinib short­com­ings, trig­ger­ing a new rout on stock price

AB Sci­ence has just stum­bled in­to an­oth­er set­back with its all-pur­pose an­ti-in­flam­ma­to­ry drug ma­sitinib. 

The Paris-based biotech run by founder Alain Moussy says that the CHMP has adopt­ed a neg­a­tive stance on ap­prov­ing the drug for ALS. And once again re­searchers drew some poor grades on tri­al de­sign and ex­e­cu­tion.

In a re­lease the biotech said that the CHMP not­ed that “the re­li­a­bil­i­ty of the da­ta was not ro­bust enough to sup­port a reg­is­tra­tion.” They were al­so con­cerned about the pos­si­bil­i­ty of bias be­ing in­tro­duced in­to their analy­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER